Logo image of HGEN

HUMANIGEN INC (HGEN) Stock Fundamental Analysis

NASDAQ:HGEN - Nasdaq - US4448632038 - Common Stock - Currency: USD

0.0361  -0.16 (-81.12%)

After market: 0.0358 0 (-0.83%)

Fundamental Rating

1

Overall HGEN gets a fundamental rating of 1 out of 10. We evaluated HGEN against 563 industry peers in the Biotechnology industry. Both the profitability and financial health of HGEN have multiple concerns. HGEN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HGEN has reported negative net income.
In the past year HGEN has reported a negative cash flow from operations.
HGEN had negative earnings in each of the past 5 years.
In the past 5 years HGEN always reported negative operating cash flow.
HGEN Yearly Net Income VS EBIT VS OCF VS FCFHGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M -200M

1.2 Ratios

The profitability ratios for HGEN are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HGEN Yearly ROA, ROE, ROICHGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5K -5K 10K 15K

1.3 Margins

HGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HGEN Yearly Profit, Operating, Gross MarginsHGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K -20K -25K

More info and screens

0

2. Health

2.1 Basic Checks

HGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HGEN has been increased compared to 1 year ago.
There is no outstanding debt for HGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HGEN Yearly Shares OutstandingHGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
HGEN Yearly Total Debt VS Total AssetsHGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -232.21, we must say that HGEN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -232.21, HGEN is not doing good in the industry: 99.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -232.21
ROIC/WACCN/A
WACC11.19%
HGEN Yearly LT Debt VS Equity VS FCFHGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M

2.3 Liquidity

HGEN has a Current Ratio of 0.09. This is a bad value and indicates that HGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.09, HGEN is not doing good in the industry: 99.66% of the companies in the same industry are doing better.
A Quick Ratio of 0.09 indicates that HGEN may have some problems paying its short term obligations.
The Quick ratio of HGEN (0.09) is worse than 99.66% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
HGEN Yearly Current Assets VS Current LiabilitesHGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.50% over the past year.
Looking at the last year, HGEN shows a very negative growth in Revenue. The Revenue has decreased by -59.01% in the last year.
EPS 1Y (TTM)79.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
Revenue 1Y (TTM)-59.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.67%

3.2 Future

HGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.74% yearly.
Based on estimates for the next years, HGEN will show a very strong growth in Revenue. The Revenue will grow by 110.13% on average per year.
EPS Next Y83.55%
EPS Next 2Y37.89%
EPS Next 3Y27.81%
EPS Next 5Y15.74%
Revenue Next Year-91.42%
Revenue Next 2Y-41.42%
Revenue Next 3Y165.44%
Revenue Next 5Y110.13%

3.3 Evolution

HGEN Yearly Revenue VS EstimatesHGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
HGEN Yearly EPS VS EstimatesHGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HGEN. In the last year negative earnings were reported.
Also next year HGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HGEN Price Earnings VS Forward Price EarningsHGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HGEN Per share dataHGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as HGEN's earnings are expected to grow with 27.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.89%
EPS Next 3Y27.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HUMANIGEN INC

NASDAQ:HGEN (7/25/2023, 8:00:02 PM)

After market: 0.0358 0 (-0.83%)

0.0361

-0.16 (-81.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2023-05-15/bmo
Earnings (Next)08-10 2023-08-10
Inst Owners0.01%
Inst Owner Change0%
Ins Owners5.13%
Ins Owner Change0%
Market Cap4.30M
Analysts43.33
Price Target0.15 (315.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.85%
Min EPS beat(2)34.64%
Max EPS beat(2)179.06%
EPS beat(4)2
Avg EPS beat(4)36.56%
Min EPS beat(4)-42.54%
Max EPS beat(4)179.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)116.67%
Min Revenue beat(2)116.67%
Max Revenue beat(2)116.67%
Revenue beat(4)2
Avg Revenue beat(4)51.22%
Min Revenue beat(4)-58.33%
Max Revenue beat(4)116.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-53.85%
PT rev (3m)-53.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)41.75%
EPS NY rev (3m)41.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.53
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0.01
BVpS-0.42
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z -232.21
F-Score3
WACC11.19%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
EPS Next Y83.55%
EPS Next 2Y37.89%
EPS Next 3Y27.81%
EPS Next 5Y15.74%
Revenue 1Y (TTM)-59.01%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.67%
Revenue Next Year-91.42%
Revenue Next 2Y-41.42%
Revenue Next 3Y165.44%
Revenue Next 5Y110.13%
EBIT growth 1Y72.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.92%
EBIT Next 3Y21.33%
EBIT Next 5Y-8.13%
FCF growth 1Y38.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.78%
OCF growth 3YN/A
OCF growth 5YN/A